The standard escalation from 2.5 mg to 5 mg occurs at 4 weeks, but some patients benefit from extending each dose level to 6-8 weeks before escalating
Routine monitoring of electrolytes, including potassium, is not universally required for all patients on semaglutide, but certain clinical scenarios warrant closer surveillance as outlined in NICE guidance (NG28)
Patients should disclose GLP-1 treatments obtained from private clinics or online providers because they may not automatically appear in NHS medical records
Still, they may include restoring blood flow through surgical procedures, managing any underlying conditions contributing to the ischemia, and providing supportive care
Local signs of infection include progressive erythema extending beyond the immediate injection site, warmth, fluctuance suggesting abscess formation, or purulent drainage
reported that GLP1RAs, regardless of structural homology, reduced the risk of major adverse cardiovascular events (i.e., 3point major adverse cardiovascular events (MACE), including nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) by 14% (HR 0.86, 95% CI 0.800.93), allcause mortality by 12% (HR 0.88, 95% CI 0.820.94) and hospital admissions for heart failure by 11% (HR 0.89, 95% CI 0.820.98) [45]